Dental Pain (Following Third Molar Tooth Extraction) Study
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00114049|
Recruitment Status : Completed
First Posted : June 14, 2005
Last Update Posted : January 19, 2017
|Condition or disease||Intervention/treatment||Phase|
|Dental Pain Surgery, Dental||Drug: GW406381||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||300 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||A Pivotal Phase III, Single Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Dose-Ranging Study to Investigate the Efficacy and Safety of Single Oral Doses of 10mg, 25mg, 50mg and 70mg GW406381 and 550mg Naproxen Sodium in Subjects With Pain Following Third Molar Tooth Extraction|
|Study Start Date :||December 2004|
|Actual Primary Completion Date :||April 2005|
|Actual Study Completion Date :||April 2005|
- Difference between treatments over time based on pain intensity and pain relief scores.
- Difference between treatments based on changes in onset, duration of activity, overall effectiveness, and patient based assessments.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00114049
|United States, Texas|
|GSK Investigational Site|
|Austin, Texas, United States, 78703|
|Study Director:||GSK Clinical Trials, MD||GlaxoSmithKline|